mTOR and tyrosine kinase inhibitors may play an increasing role in the management of well-differentiated neuroendocrine tumors in the future. Peptide receptor radiotherapy is a new treatment ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...